Vascular in Medical Technology

Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System

... April 2005. According to the Society of vascular Surgery, physicians diagnose approximately ... and is the U.S. distributor for Vascutek(R) vascular Grafts. The company is headquartered in Ann ... Japan that is focused exclusively on cardiac and vascular specialties, including Terumo Heart Inc., ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, ... 2, 2009. The presentation for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as ... Poster Phase I evaluation of SF1126 a vascular targeted PI3K Title: inhibitor ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... said James McKinsey, M.D., Interim Chief of vascular Surgery of New York Presbyterian Hospital System ... Cardiology and Associate Director of vascular Medicine at St. Elizabeth's Medical Center, ... of diabetic patients in this very difficult vascular territory." Robert Palmisano, ev3's ...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... abnormal new blood vessels that are mediated by vascular endothelial growth factor (VEGF), we are hopeful ... Release of VEGF contributes to increased vascular permeability in the eye and abnormal new vessel ... that anti-VEGF treatment may help decrease vascular permeability and edema and prevent the growth of ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... online at www.xiencev.com . About Abbott vascular Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... to research and develop innovative devices in vascular care. Abbott's robust vascular research program includes clinical trials in ... and coronary artery disease. Key products in the vascular pipeline include: the Omnilink Elite(TM) ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... anti-proliferative properties. About Abbott vascular Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment ...

For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold

... "Elderly patients' arteriovenous (AV) fistulas -- vascular accesses needed for dialysis treatment -- ... and their doctors is keeping an individual's vascular access graft open for dialysis. AV fistulas ... said Forauer. Before dialysis can begin, a vascular access, which is the site on a patient's body ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... at http://www.xiencev.com . About Abbott vascular Abbott Vascular, a division of Abbott, is ... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining ...

Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries

... procedures performed at Baptist Cardiac & vascular Institute, Miami. The radial approach also is ... cardiology at Baptist Cardiac & vascular Institute, and ISET course director. "The radial ... infection and death. At Baptist Cardiac & vascular Institute, the complication rates for the radial ...

Chemoembolization Improving as Liver Cancer Treatment

... beyond just palliation," said Glenn Stambo, M.D., vascular and interventional radiologist at St. Joseph's ... the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET is presented by the Baptist Cardiac & vascular Institute, Miami. ISET 2009 is taking place Jan. ...

Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

... from forming. Alan M. Dietzek, MD, Chief of vascular and Endovascular Surgery at Danbury Hospital, ... www.DVT-Revolution.org . About Bacchus vascular Bacchus Vascular, Inc. is a privately ... company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor ...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

... on novel therapies for eye disease, vascular disease and cancer, announces positive results ... Moreover, of the patients who had more severe vascular blockages, 33% of patients treated with ... is able to lyse clots and may also have certain vascular protective properties." Dr. Patrik De Haes, CEO ...

Cytopia Commences Second Phase II Study in Brain Cancer

... of less than 12 months. GBM tumors are highly vascular and heavily dependent on their own abnormal blood ... markers of vascular disruption and tumor apoptosis, ... This key finding differentiates CYT997 from other vascular disrupting agents currently in development which ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

... -- Death during infusion has been reported. vascular Leak Syndrome -- This syndrome, characterized ... -- The onset of symptoms in patients with vascular leak syndrome was delayed, usually occurring ... cessation of denileukin diftitox. -- Cases of vascular (capillary) leak with a fatal outcome have ...

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering

... that early blockade of angiotensin II reversed vascular hypertrophy ... medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage ... receptor blockers in preventing or reversing vascular damage at many stages during this disease ...

PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)

... ), a company focused on innovative cardiac and vascular medical device-based technologies, announced ... use of contrast media for coronary and peripheral vascular diagnostic and interventional procedures in ... in innovative technologies for the cardiac and vascular markets. PLC's newest product program, ...

Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes

... with the disease often continue to experience vascular dysfunction. This has led scientists on a search ... consumption of a flavanol-rich cocoa drink on vascular function in diabetic adults was investigated. In ... by the magnitude of impact of cocoa flavanols on vascular function in these diabetic adults," said ...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

... taking notice of the critical role of EPCs in the vascular healing process. The Genous EPC capture ... which moves the cardiologists into the realm of vascular biology." Unlike drug-eluting stents, Genous, ... innovative medical devices for the treatment of vascular diseases. The company's product portfolio ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ... effectiveness in treating patients with vascular disease. About Abbott Abbott (NYSE: ABT ) is ...

CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic

... Jose Navia, a cardiac surgeon with the Heart and vascular Institute at the Cleveland Clinic. The method ... agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to ...

Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent

... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ... effectiveness in treating patients with vascular disease. About Abbott Abbott (NYSE: ABT ) is ...

Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years

... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ... effectiveness in treating patients with vascular disease. About Abbott Abbott (NYSE: ABT ) is ...

Anti-Cancer Drug CYT997 Update

... of a suite of Phase II clinical studies for its vascular disrupting agent (VDA), CYT997. These studies ... intends to investigate the activity of its own vascular targeting agent CYT997 in this setting. This ... cancer therapies best synergize with CYT997's vascular targeting properties. Data from these studies ...

Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105

... BNC105 is a new type of anti-cancer drug called a vascular Disruption Agent (VDA) which blocks the blood ... Dose-Escalation Study of BNC105P, a Novel vascular Disrupting Agent, In Patients with Advanced Solid ... kinetic parameters directly related to tumour vascular characteristics using DCE-MRI. * To show ...

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

... Inc. TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based ... small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. ...

ImaRx Therapeutics Transitions Business Strategy

... commercializing and developing therapies for vascular disorders. The Company's commercialization ... are focused on therapies for stroke and other vascular disorders using its proprietary ... inventory and expand product sales to additional vascular physicians and acute care institutions. About ...

VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

... to measure VIA-2291's ability to reduce vascular inflammation in treated patients. The company ... for measuring the effect of VIA-2291 in reducing vascular inflammation. "We are pleased with the progress ... and clinical activity of VIA-2291 to reduce vascular inflammation, and therefore, the risk of ...

YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter

... for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where ... from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention providing less invasive therapy for ...

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

... Inc. TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based ... small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. ...

Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

... Leap Forward", Alan Dietzek, MD., Chief of vascular Surgery and Linda and Stephen R Cohen Chair in vascular Surgery at Danbury Hospital in Danbury, ... Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, ...

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

... Professor, Department of Medicine; Director, vascular Biology Center of Excellence, University ... with acute coronary syndromes or established vascular disease," added Veltri. The results were ... process is the underlying mechanism of most acute vascular events, including acute coronary syndromes (ACS), ...

VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis

... officer of VIA. "By targeting this key pathway in vascular inflammation, we believe VIA-2291 may have the ... powerful anti-inflammatory compound for the vascular system." Atherosclerosis is the result of ... lesions. These cells are often implicated in vascular inflammation in atherosclerosis. The study used ...

Cardiologists Tackle 'Next Frontier' in Cardiovascular Disease

... increase the number of people with vascular disease in coming years, experts say. "As we ... "These advances in the treatment of peripheral vascular disease are the next frontier in cardiovascular ... live cases during the TCT symposium. Peripheral vascular disease is a common condition affecting about ...

ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting

... Medical Director, Massachusetts General Hospital vascular Center, Boston, Massachusetts, Chair of the ... events. Chlamydia pneumoniae infection of the vascular system has long been thought to play a role in accelerating the course of vascular disease potentially by increasing inflammation in ...

Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

... and Medical Director of Baptist Cardiac and vascular Institute, and co-principal investigator for The ... John R. Laird, M.D., Medical Director of the vascular Center at the University of California, Davis ... including heart valve disease, peripheral vascular disease and critical care technologies. The ...

Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

... . About Abbott vascular Abbott Vascular, a division of Abbott, is one of ... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

... . About Abbott vascular Abbott Vascular, a division of Abbott, is one of ... world's leading vascular care businesses. Abbott vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by ...

Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies

... in the September 2007 issue of the Journal of vascular Surgery. Presented in the leading subspecialty, ... author and medical director of Peripheral vascular Services at the Arizona Heart Institute. "In our ... and sudden death. According to the Society for vascular Surgery, less than half of all patients who ...

Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

... Foltz, vice president, Abbott Vascular. "Abbott vascular has a strong history of innovation and leadership in vascular care, and with the HERCULES trial we can continue to expand our understanding of vascular disease and how to deliver the best treatments ...